Overall rank by patents
#48,517
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 11 technology areas, active 2016–2019. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
The verdict
Macopharma holds 5 US patents across 11 technology areas, rank #48,517 of 50,000 tracked assignees.
Macopharma, S.a.s. has been granted 5 US utility patents between 2016 and 2019, placing Macopharma, S.a.s. at rank #48,517 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 25.8 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a Foreign Corporation, Macopharma, S.a.s. is one of the more focused assignees in the PatentsView dataset. By volume, Macopharma sits between M.t.a. S.p.a. (5 patents, rank #48,513) and Madme Technologies Limited (5 patents, rank #48,521) - the closest US assignees by grant volume. The composite Innovation Score of 32.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 5 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Macopharma, S.a.s.'s 25.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Macopharma, S.a.s. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
M.T.A. S.P.A.
5 patents
M2S CO., LTD
5 patents
MACFARLAN SMITH LIMITED
5 patents
MACHINE GUN ARMORY, L.L.C.
5 patents
MACTAGGART SCOTT (HOLDINGS) LIMITED
5 patents
MAD STREET DEN, INC.
5 patents
MADICO, INC.
5 patents
MADME TECHNOLOGIES LIMITED
5 patents
MACOPHARMA, S.A.S.
5 patents
What this shows Macopharma holds 5 patents at rank #48,517, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #48,517 in granted patent volume.
Other assignees with the most granted patents in Macopharma's primary technology class.
Macopharma's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
33 Top 57% higher than 43% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 40.0% |
| 2018 | 2 | 40.0% |
| 2019 | 1 | 20.0% |
Top 11 of 11 technology areas
Overall rank by patents
#48,517
Across all tracked assignees
32.9 out of 100
How to use this portfolio
Macopharma's 5 grants land it in the top 57% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.